Genprex Inc, a US-based gene therapy company, has raised $6.5 million from a direct share offering to support its gene therapy programmes for cancer and diabetes. Announced on 22 March, the funding will support development of the company’s nanoparticle technology for delivering functional genes to the body, as well as a new AAV vector approach.
